EXPERT HIGHLIGHTS: RENAL CELL CARCINOMA
SIU Academy®. Faculty / Presenter(s) . 11/07/20; 312684
Topic: Kidney cancer
Faculty / Presenter(s)
About this activity
The treatment landscape for RCC is in an era of rapid progression with multiple exciting trials and ongoing pre-clinical studies. These promising new emerging therapies will likely continue to improve outcomes in patients with RCC. With these advances, there is an urgent need in the urological community to stay up-to-date with current guidelines and apply this knowledge to improve the outcomes for patients with RCC.
Faculty:
Moderator:
Thomas Powles, MBBS, MRCP, MD
Director, Barts Cancer Centre
Cancer Research UK
Brian Rini, MD, FASCO
Vanderbilt University Medical Center
Nashville, TN
Kala S. Sridhar MD, MSc, FRCPC
Medical Oncologist, Princess Margaret Hospital
Associate Professor, University of Toronto
Chair, GU Medical Oncologists of Canada
Toronto, Ontario, CANADA
This educational activity is made possible through the financial support of Merck Canada Inc. The opinions expressed are those of its authors and do not necessarly refleft the views and opinions of Merck Canada Inc.
Faculty:
Moderator:
Thomas Powles, MBBS, MRCP, MD
Director, Barts Cancer Centre
Cancer Research UK
Brian Rini, MD, FASCO
Vanderbilt University Medical Center
Nashville, TN
Kala S. Sridhar MD, MSc, FRCPC
Medical Oncologist, Princess Margaret Hospital
Associate Professor, University of Toronto
Chair, GU Medical Oncologists of Canada
Toronto, Ontario, CANADA
This educational activity is made possible through the financial support of Merck Canada Inc. The opinions expressed are those of its authors and do not necessarly refleft the views and opinions of Merck Canada Inc.
{{ help_message }}